ERG orchestrates chromatin interactions to drive prostate cell fate reprogramming.

Area of Science:

• Molecular Biology
• Cancer Research
• Epigenetics

Background:

• Prostate cancer initiation involves abnormal proliferation of differentiated luminal cells, contrasting with the typical dedifferentiation seen in other cancers.
• The precise mechanisms driving this proluminal differentiation in prostate cancer remain largely unelucidated.
• Understanding lineage plasticity is crucial for developing targeted therapies.

Purpose of the Study:

• To investigate the role of transcription factors (TFs) in prostate cancer luminal subtyping.
• To elucidate the mechanism by which ERG influences prostate cancer cell lineage differentiation.
• To identify the regulatory pathways controlling prostate cancer cell fate.

Main Methods:

• Integrated analysis of transcription factor data from 806 human prostate cancer samples.
• Experimental manipulation of ERG and AR (androgen receptor) in prostate cells.
• 3D chromatin architecture analysis to study enhancer activity and chromatin looping.

Main Results:

• ERG overexpression strongly correlated with prostate cancer luminal subtyping and inhibited luminal cell plasticity towards basal lineage differentiation.
• ERG, not PTEN loss or AR, was identified as a key regulator of luminal differentiation; ERG knockout disrupted this process.
• ERG directly bound to and inhibited a distal Trp63 enhancer, silencing basal lineage gene expression and promoting a proluminal program.

Conclusions:

• ERG plays a fundamental role in prostate cancer initiation by orchestrating chromatin interactions.
• ERG actively directs prostate cell lineage towards a proluminal differentiation program, overriding normal basal cell plasticity.
• Targeting ERG-mediated epigenetic regulation offers a potential therapeutic strategy for prostate cancer.